Salarius Pharmaceuticals, Inc. (SLRX:NASDAQ) closed at $0.840 on January 7, 2026, up 29.23% on the day. The stock trades 98.4% below its 52-week high of $52.95 and 63.1% above its 52-week low of $0.515. Salarius Pharmaceuticals, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 23, 2025, SLRX closed higher on 26 days (10%). Its best day was January 13, 2026 (+53.37%) and its worst was November 11, 2025 (-51.00%). The stock moved 10% or more in a single session 13 times. It opened at least 5% above the previous day's high 3 times.
Flex Pharma Inc is a US-based biotechnology company which is engaged in the developing proprietary treatments for muscle cramps and spasms associated with severe neurological conditions and exercise-associated muscle cramps. The lead drug product candidate is FLX-787 which is a single molecule, chemically synthesized, TRP ion channel activator and HOTSHOT, which is developed to prevent and treat exercise-associated muscle cramps. It operates through two segments - Consumer Operations and Drug Development. The Consumer Operations segment includes the development of HOTSHOT whereas the Drug Development segment includes the development of proprietary drug products to treat muscle cramps and spasms associated with severe neurological conditions.
Find more stocks like SLRX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.